Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$28.30 USD

28.30
37,883,682

-0.22 (-0.77%)

Updated Oct 31, 2024 04:00 PM ET

After-Market: $28.34 +0.04 (0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 21% (53 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: SNY, RHHBY, PFE's Coronavirus Product Development & Other Updates

Pfizer (PFE) is set to jointly develop BioNTech's potential coronavirus vaccine. Regeneron/Sanofi (SNY) and Roche will study their RA drugs, Kevzara & Actemra, respectively to treat severe COVID-19 infection.

Nitish Marwah headshot

4 Dividend Stocks to Buy Amid the Coronavirus Rout

The coronavirus has dealt a huge blow to markets globally. Valuations have gone for a toss across every asset class and sector.

Pfizer's Eczema Drug & Pneumococcal Vaccine Succeed in Study

Pfizer's (PFE) atopic dermatitis (eczema) candidate, abrocitinib, and pneumococcal conjugate vaccine candidate meet primary endpoints in their respective late-stage studies.

Pfizer (PFE) Gains As Market Dips: What You Should Know

Pfizer (PFE) closed the most recent trading day at $32.40, moving +0.75% from the previous trading session.

Merck's Chronic Cough Candidate Achieves Goals in Phase III

Merck's (MRK) two phase III studies on gefapixant (MK-7264) for the treatment of refractory or unexplained chronic cough meet the primary efficacy endpoints.

Kinjel Shah headshot

Pfizer, Regeneron Give Update on Coronavirus Drug Development

Pfizer (PFE) to jointly develop BioNTech's potential coronavirus vaccine. Regeneron (REGN) could start clinical studies of a COVID-19 therapy by this summer.

Company News for Mar 18, 2020

Companies In The News Are: PFE, BNTX, REGN, DNKN. TMO.

Lilly's Olumiant Gets Breakthrough Therapy Tag for Hair Loss

The FDA grants breakthrough therapy status to Eli Lilly's (LLY) oral JAK inhibitor, Olumiant (baricitinib) for potential treatment of alopecia areata, an autoimmune disorder leading to hair loss.

Moderna Up as First Human Trial of Coronavirus Vaccine Begins

Moderna (MRNA) announces dosing of first human in a phase I clinical study evaluating its coronavirus vaccine candidate. The National Institutes of Health is conducting the study.

Pfizer (PFE) Catches Eye: Stock Jumps 9%

Pfizer (PFE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Emergent BioSolutions Collaborates for Coronavirus Vaccine

Emergent BioSolutions' (EBS) collaborates with Novavax to support production of the latter's coronavirus vaccine and advance it to clinical stage development.

Mylan-Upjohn Merger in Focus, Coronavirus Might Hit Supply

Mylan's (MYL) merger with Upjohn is in focus as the former looks to revive its business. However, the coronavirus epidemic can hit the company's supply-chain operations.

Allergan's (AGN) Glaucoma Implant Durysta Gets FDA Approval

Allergan's (AGN) Durysta (bimatoprost) gets FDA approval to reduce intraocular pressure in patients with open-angle glaucoma.

Kinjel Shah headshot

Pharma Stock Roundup: Trump, Pharma Executives Meeting on Coronavirus, FDA Updates

Trump asks pharma firms to accelerate development of coronavirus vaccine/treatment. FDA approves Sanofi's (SNY) Sarclisa and Allergan'sa (AGN) Durysta.

The Zacks Analyst Blog Highlights: Walmart, Pfizer, Charter Communications, Lockheed Martin and CME

The Zacks Analyst Blog Highlights: Walmart, Pfizer, Charter Communications, Lockheed Martin and CME

Sweta Killa headshot

Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

Sector ETF report for PPH

Mark Vickery headshot

Top Stock Reports for Walmart, Pfizer & Charter Communications

Today's Research Daily features new research reports on 16 major stocks, including Walmart (WMT), Pfizer (PFE) and Charter Communications (CHTR).

Inovio Surges on Expedited Timeline for Coronavirus Vaccine

Inovio (INO) to initiate human clinical studies on INO-4800, its DNA vaccine, this April, for the treatment of the deadly coronavirus. The stock price shoots up.

Lilly Expects No Drug Supply Shortages Due to Coronavirus

Lilly (LLY) does not expect shortage in supply of its medicines as it does not source APIs of any of its marketed drugs from China.

Sanofi's Sarclisa Gets FDA Nod for Third-Line Multiple Myeloma

The FDA approves Sanofi's (SNY) Sarclisa (isatuximab) combo for the treatment of adult patients with relapsed refractory multiple myeloma in the third-line setting.

Roche's Esbriet Gets FDA Breakthrough Tag for New Indication

Roche (RHHBY) gets Breakthrough Therapy status from the FDA for Esbriet in adults with unclassifiable interstitial lung disease.

Pfizer Plans Coronavirus Therapy, Progresses With Tanezumab BLA

Pfizer (PFE) identifies potential antiviral compounds to develop a treatment for coronavirus disease. The FDA accepts regulatory application seeking approval for tanezumab for osteoarthritis.

Merck's Keytruda Improves PFS in Phase III Lymphoma Study

Merck's (MRK) Keytruda significantly improves progression-free survival compared with brentuximab vedotin in patients with relapsed or refractory classical Hodgkin Lymphoma (cHL)

Is the Options Market Predicting a Spike in Pfizer (PFE) Stock?

Investors need to pay close attention to Pfizer (PFE) stock based on the movements in the options market lately.

Is Pfizer (PFE) Stock a Solid Choice Right Now?

Pfizer (PFE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.